New tracer could reveal hidden immune activity in brain diseases

NCT ID NCT05849467

Recruiting now Knowledge-focused Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests whether a radioactive tracer called 89Zr-Df-crefmirlimab can help PET scans detect certain immune cells (CD8+ T cells) in the brain and spinal cord of people with multiple sclerosis (MS) or progressive multifocal leukoencephalopathy (PML). About 15 adults will receive the tracer and undergo PET and MRI scans over several weeks. The goal is to better understand how these diseases affect the central nervous system.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 89Zr-Df-crefmirlimab (a radioactive tracer that binds to CD8+ T cells)
What this could lead to: If successful, this could provide a new way to see where immune cells are active in the brain, helping researchers understand MS and PML better.
What could go wrong: This is a very small, early-phase pilot study with only 15 participants. The tracer may not work as expected, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis progressive multifocal leukoencephalopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS OTHER NEUROINFLAMMATORY DISEASES WITH BBB LEAKAGE PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.